Equity and representation in oncology clinical evidence for FDA-approved treatments and the impact of COVID-19 - Top-Institutions - MDSpire

Equity and representation in oncology clinical evidence for FDA-approved treatments and the impact of COVID-19

  • By

  • Hao Cheng

  • Jun Li

  • Ningying Mao

  • May 1, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

  • #2

    National Cancer Institute
    National Cancer Institute

    Bethesda, Maryland

    Key Differentiators

    • Oncology

  • #3

    American Society of Clinical Oncology (ASCO)
    American Society of Clinical Oncology (ASCO)

    Alexandria, Virginia

    Key Differentiators

    • Oncology

  • #4

    Columbia University’s Herbert Irving Comprehensive Cancer Center
    Columbia University’s Herbert Irving Comprehensive Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

  • #5

    The Ohio State University Comprehensive Cancer Center
    The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

    Key Differentiators

    • Oncology

Original Source(s)

Equity and representation in oncology clinical evidence for FDA-approved treatments and the impact of COVID-19

  • by Hao Cheng, Jun Li, Ningying Mao

  • May 1, 2026

Related Content

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”